HLA-DQ genotypes in classic type 1 diabetes and in latent autoimmune diabetes of the adult

American Journal of Epidemiology

Volumn 156, Issue 9, 2002, Pages 787-796

  Stenström, Gunnar ^a,e   Berger, Bo ^b   Borg, Henrik ^c   Fernlund, Per ^c   Dorman, Janice S ^d   Sundkvist, Göran ^c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b CENTRAL HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e Kungsbacka Hospital   (Sweden)

Author keywords

Autoantibodies; C peptide; Diabetes mellitus, insulin dependent; Diabetes mellitus, non insulin dependent; HLA DQ antigens; Islets of Langerhans

Indexed keywords

AUTOANTIBODY; C PEPTIDE; GLUTAMATE DECARBOXYLASE; HLA DQ ANTIGEN; INSULIN; IODINE 125; PANCREAS ISLET CELL ANTIBODY; RECOMBINANT ENZYME;

DIABETES;

ADULT; ANTIBODY DETECTION; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; FEMALE; GENOTYPE; HLA TYPING; HUMAN; IMMUNOFLUORESCENCE TEST; INSULIN DEPENDENT DIABETES MELLITUS; ISOTOPE LABELING; LIGAND BINDING; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET; POLYMERASE CHAIN REACTION;

AGE FACTORS; AUTOANTIBODIES; C-PEPTIDE; CHI-SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HLA-DQ ANTIGENS; HUMANS; MALE; REGISTRIES; STATISTICS, NONPARAMETRIC; SWEDEN;

EID: 0036841760     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/aje/kwf115     Document Type: Article

References (55)

1. Nerup J, Platz P, Andersen OO, et al. HL-A antigens and diabetes mellitus. Lancet 1974;2:864-6.
2. Bertrams J, Barr M. Histocompatibility Testing. Heidelberg, Germany: Springer-Verlag, 1984.
3. Morel PA, Dorman JS, Todd JA, et al. Aspartic acid at position 57 of the HLA-DQ beta chain protects against type I diabetes: A family study. Proc Natl Acad Sci U S A 1988;85:8111-15.
4. Todd JA, Acha-Orbea H, Bell JI, et al. A molecular basis for MHC class II-associated autoimmunity. Science 1988;240:1003-9.
5. Trucco M, Dorman JS. Immunogenetics of insulin-dependent diabetes mellitus in humans. Crit Rev Immunol 1989;9:201-45.
6. Baisch JM, Weeks T, Giles R, et al. Analysis of HLA-DQ genotypes and susceptibility in insulin-dependent diabetes mellitus. N Engl J Med 1990;322:1836-41.
7. Pugliese A, Gianani R, Moromisato R, et al. HLA-DQB1 *0602 is associated with dominant protection from diabetes even among islet cell antibody-positive first-degree relatives of patients with IDDM. Diabetes 1995;44:608-13.
8. Svejgaard A, Jakobsen BK, Platz P, et al. HLA associations in insulin-dependent diabetes: Search for heterogeneity in different groups of patients from a homogeneous population. Tissue Antigens 1986;28:237-44.
9. Heimberg H, Nagy ZP, Somers G, et al. Complementation of HLA-DQA and -DQB genes confers susceptibility and protection to insulin-dependent diabetes mellitus. Hum Immunol 1992;33:10-17.
10. Vandewalle CL, Decraene T, Schuit FC, et al. Insulin autoantibodies and high titre islet cell antibodies are preferentially associated with the HLA DQA1 *0301-DQB1 *0302 haplotype at clinical type 1 (insulin-dependent) diabetes mellitus before age 10 years, but not at onset between age 10 and 40 years. The Belgian Diabetes Registry. Diabetologia 1993;36:1155-62.
11. Kockum I, Lernmark Å, Dahlquist G, et al. Genetic and immunological findings in patients with newly diagnosed insulindependent diabetes mellitus. The Swedish Childhood Diabetes Study Group and the Diabetes Incidence in Sweden Study (DISS) Group. Horm Metab Res 1996;28:344-7.
12. Vandewalle CL, Falorni A, Lernmark Å, et al. Associations of GAD65- and IA-2-autoantibodies with genetic risk markers in new-onset IDDM patients and their siblings. The Belgian Diabetes Registry. Diabetes Care 1997;20:1547-52.
13. Vandewalle CL, Coeckelberghs MI, De Leeuw IH, et al. Epidemiology, clinical aspects, and biology of IDDM patients under age 40 years. Comparison of data from Antwerp with complete ascertainment with data from Belgium with 40% ascertainment. The Belgian Diabetes Registry. Diabetes Care 1997;20:1556-61.
14. Lohmann T, Sessler J, Verlohren HJ, et al. Distinct genetic and immunological features in patients with onset of IDDM before and after age 40. Diabetes Care 1997;20:524-9.
15. Graham J, Kockum I, Sanjeevi CB, et al. Negative association between type 1 diabetes and HLA DQB1 *0602- DQA1 *0102 is attenuated with age at onset. Swedish Childhood Diabetes Study Group. Eur J Immunogenet 1999;26:117-27.
16. Molbak AG, Christau B, Marner B, et al. Incidence of insulin-dependent diabetes mellitus in age groups over 30 years in Denmark. Diabet Med 1994;11:650-5.
17. Caillat-Zucman S, Garchon HJ, Timsit J, et al. Age-dependent HLA genetic heterogeneity of type 1 insulin-dependent diabetes mellitus. J Clin Invest 1992;90:2242-50.
18. Karjalainen J, Salmela P, Ilonen J, et al. A comparison of childhood and adult type I diabetes mellitus. N Engl J Med 1989;320:881-6.
19. Awata T, Hagura R, Urakami T, et al. Age-dependent HLA genetic heterogeneity of IDDM in Japanese patients. (Letter). Diabetologia 1995;38:748-9.
20. Chan S, Thai A, Lin Y, et al. Influence of gender and age at onset on the HLA associations in Chinese with insulin-dependent diabetes mellitus. Hum Immunol 1995;44:175-80.
21. Tait B, Harrison L, Drummond B, et al. HLA antigens and age at diagnosis of insulin-dependent diabetes mellitus. Hum Immunol 1995;42:116-22.
22. Sabbah E, Savola K, Ebeling T, et al. Genetic, autoimmune, and clinical characteristics of childhood- and adult-onset type 1 diabetes. Diabetes Care 2000;23:1326-32.
23. Gottsäter A, Landin-Olsson M, Fernlund P, et al. Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients. Diabetes Care 1993;16:902-10.
24. Hagopian WA, Karlsen AE, Gottsäter A, et al. Quantitative assay using recombinant human islet glutamic acid decarboxylase (GAD65) shows that 64K autoantibody positivity at onset predicts diabetes type. J Clin Invest 1993;91:368-74.
25. Tuomi T, Groop LC, Zimmet PZ, et al. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 1993;42:359-62.
26. Tuomi T, Carlsson Å, Li H, et al. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 1999;48:150-7.
27. Humphrey AR, McCarty DJ, Mackay IR, et al. Autoantibodies to glutamic acid decarboxylase and phenotypic features associated with early insulin treatment in individuals with adult-onset diabetes mellitus. Diabet Med 1998;15:113-19.
28. Borg H, Gottsäter A, Landin-Olsson M, et al. High levels of antigen-specific islet antibodies predict future β-cell failure in patients with onset of diabetes in adult age. J Clin Endocrinol Metab 2001;86:3032-8.
29. Zimmet P, Turner R, McCarty D, et al. Crucial points at diagnosis. Type 2 diabetes or slow type 1 diabetes. Diabetes Care 1999;22(suppl 2):B59-64.
30. Juneja R, Palmer JP. Type 1 1/2 diabetes: Myth or reality? Autoimmunity 1999;29:65-83.
31. Groop LC, Bottazzo GF, Doniach D. Islet cell antibodies identify latent type I diabetes in patients aged 35-75 years at diagnosis. Diabetes 1986;35:237-41.
32. Zimmet PZ, Tuomi T, Mackay IR, et al. Latent autoimmune diabetes mellitus in adults (LADA): The role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med 1994;11:299-303.
33. Pozzilli P, Di Mario U. Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): Definition, characterization, and potential prevention. Diabetes Care 2001;24:1460-7.
34. Li H, Lindholm E, Almgren P, et al. Possible human leukocyte antigen-mediated genetic interaction between type 1 and type 2 diabetes. J Clin Endocrinol Metab 2001;86:574-82.
35. Berger B, Stenström G, Chang YF, et al. The prevalence of diabetes in a Swedish population of 280,411 inhabitants. A report from the Skaraborg Diabetes Registry. Diabetes Care 1998;21:546-8.
36. Diabetes Mellitus. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1985;727:1-113.
37. Dorman S, Kosova M, O'Leary L, et al. Case-control Molecular Epidemiology Studies: Standards for the WHO DIAMOND Project. New York, NY: Plenum Press, 1994.
38. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
39. Fernandez-Vina MA, Bignon JD. Primers and oligonucleotide probes (SSOP) used for DNA typing of HLA class II alleles. In: Charron D, ed. Genetic Diversity of HLA: Functional and Medical Implications. Paris, France: EDK Press, 1997:596-632.
40. Bodmer JG, Marsh SG, Albert ED, et al. Nomenclature for factors of the HLA system, 1994. Hum Immunol 1994;41:1-20.
41. Bruno G, De Salvia A, Arcari R, et al. Clinical, immunological, and genetic heterogeneity of diabetes in an Italian population-based cohort of lean newly diagnosed patients aged 30-54 years. Diabetes Care 1999;22:50-5.
42. Madsbad S, Krarup T, McNair P, et al. Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus. Acta Med Scand 1981;210:153-6.
43. Gjessing HJ. C-peptide used in the estimation of islet beta-cell function in diabetes. Dan Med Bull 1992;39:438-52.
44. Olsson ML, Sundkvist G, Lernmark Å. Prolonged incubation in the two-colour immunofluorescence test increases the prevalence and titres of islet cell antibodies in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1987;30:327-32.
45. Borg H, Fernlund P, Sundkvist G. Measurement of antibodies against glutamic acid decarboxylase 65 (GADA): Two new 125I assays compared with [35S]GAD 65-ligand binding assay. Clin Chem 1997;43:779-85.
46. Borg H, Marcus C, Sjöblad S, et al. Islet cell antibody frequency differs from that of glutamic acid decarboxylase/IA2 antibodies after diagnosis of diabetes. Acta Paediatr 2000;89:46-51.
47. Borg H, Gottsäter A, Fernlund P, et al. A 12-year prospective study of the relationship between islet antibodies and beta-cell function at and after the diagnosis in patients with adult-onset diabetes. Diabetes 2002;51:1754-62.
48. Mizota M, Uchigata Y, Morizama S, et al. Age-dependent association of HLA-A24 in Japanese IDDM patients. Diabetologia 1996;39:371-3.
49. Zevaco-Mattei C, Reviron D, Atlan-Gepner C, et al. Relationship between HLA-DQ and -DR genotypes and clinical characteristics in a French population of type 1 diabetic patients. Diabet Med 1999;16:201-6.
50. Dorman JS, Bunker CH. HLA-DQ locus of the human leukocyte antigen complex and type 1 diabetes mellitus: A HuGE review. Epidemiol Rev 2000;22:218-27.
51. Khalil I, Deschamps I, Lepage V, et al. Dose effect of cis- and trans-encoded HLA-DQ alpha beta heterodimers in IDDM susceptibility. Diabetes 1992;41:378-84.
52. Pugliese A, Kawasaki E, Zeller M, et al. Sequence analysis of the diabetes-protective human leukocyte antigen-DQB1 *0602 allele in unaffected, islet cell antibody-positive first degree relatives and in rare patients with type 1 diabetes. J Clin Endocrinol Metab 1999;84:1722-8.
53. Horton V, Stratton I, Bottazzo GF, et al. Genetic heterogeneity of autoimmune diabetes: Age of presentation in adults is influenced by HLA DRB1 and DQB1 genotypes (UKPDS 43). UK Prospective Diabetes Study (UKPDS) Group. Diabetologia 1999;42:608-16.
54. Ilonen J, Reijonen H, Green A, et al. Geographical differences within Finland in the frequency of HLA-DQ genotypes associated with type 1 diabetes susceptibility. Eur J Immunogenet 2000;27:225-30.
55. Kobayashi T, Nakanishi K, Murase T, et al. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 1996;45:622-6.